Improving effective contraceptive use among opioid-maintained women

改善使用阿片类药物的女性的有效避孕方法

基本信息

  • 批准号:
    8190800
  • 负责人:
  • 金额:
    $ 30.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-01 至 2013-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The rate of unintended pregnancy among opioid-dependent women is extremely high: nearly 9 of every 10 pregnant opioid-dependent women report that the current pregnancy was unintended, a rate 2-3 times that of the general population. Despite these dire statistics, there is a dearth of scientific knowledge about contraceptive use in this population. The limited research available indicates that 75% of opioid-maintained (OM) women either use no contraception (45%) or less effective methods like condoms (30%). Development of interventions to increase contraceptive use among opioid- and other drug-dependent populations, driven primarily by efforts to reduce sexual HIV transmission rather than pregnancy prevention, has focused on condom use. However, the modest increases in condom use produced by existing interventions underscore the urgent need to develop other approaches that specifically target pregnancy prevention and promote the use of more effective contraceptives (e.g., birth control pills, IUDs, implants). The aim of this Stage I Behavioral and Integrative Treatment Development Program application is to develop and pilot test a novel contraceptive management program to increase use of more effective contraceptives among OM women. OM women (N=100) at risk for unintended pregnancy will be randomly assigned to a 6-month contraceptive management program or to usual care. The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) reinforced follow-up visits. At their first visit, participants assigned to the contraceptive management program will complete the WHO's contraception protocol, which consists of assistance choosing a contraceptive method, structured educational counseling about their chosen method, a free supply of this method, and the option of initiating their chosen method immediately at an initial contraceptive assessment visit. Subsequently, contraceptive management program participants will earn voucher-based incentives to reinforce attendance at follow-up visits where they will receive support to manage side effects and problem-solve compliance problems, refills of their chosen method, and assistance switching methods when indicated. Participants assigned to the usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services. Contraceptive use by all participants will be evaluated at assessments scheduled 1, 3, and 6 months after trial intake. The proposed project will be the seminal study of an intervention to increase more effective contraceptive use in OM women and the first step towards the overarching goal of developing an efficacious, empirically based contraceptive management program that can be disseminated to drug treatment facilities throughout the country. The proposed research also holds significant potential for impacting public health in general, as development of efficacious programs will help reduce the vast economic and societal costs associated with unintended pregnancy among drug-dependent and non-drug-dependent women alike. PUBLIC HEALTH RELEVANCE: Nearly 9 of every 10 pregnant opioid-dependent women report that the current pregnancy was unintended and the majority of non-pregnant, opioid-maintained women do not use contraception or use less effective methods like condoms. The primary aim of this application is to develop and test a novel contraceptive management program to increase use of more effective contraceptives among opioid-maintained women. The proposed research may reduce unintended pregnancy among opioid-dependent women and the knowledge gained will also have implications for addressing high rates of unintended pregnancy in the general population.
阿片类药物依赖妇女的意外怀孕率极高:每10名怀孕的阿片类药物依赖妇女中有近9名报告当前怀孕是意外的,这一比率是一般人群的2-3倍。尽管有这些可怕的统计数据,但这一人群缺乏关于避孕药具使用的科学知识。现有的有限研究表明,75%的阿片类药物维持(OM)妇女要么不使用避孕措施(45%),要么使用避孕套等效果较差的方法(30%)。制定干预措施以增加类阿片和其他药物依赖人群中避孕药具的使用,主要是为了减少艾滋病毒的性传播而不是预防怀孕,重点是避孕套的使用。然而,现有的干预措施使避孕套的使用略有增加,这突出表明迫切需要制定专门针对预防怀孕和促进使用更有效的避孕药具的其他方法(例如,避孕药、宫内节育器、植入物)。第一阶段行为和综合治疗发展方案申请的目的是开发和试点测试一种新的避孕管理方案,以增加OM妇女使用更有效的避孕药具。将有意外妊娠风险的OM女性(N=100)随机分配至6个月的避孕管理计划或常规护理。避孕管理方案将包括两个组成部分:(1)世界卫生组织的避孕方案和(2)加强随访。在第一次访问时,分配到避孕管理计划的参与者将完成世界卫生组织的避孕协议,其中包括选择避孕方法的帮助,关于他们所选择的方法的结构化教育咨询,免费提供这种方法,以及在首次避孕评估访问时立即启动他们所选择的方法的选择。随后,避孕管理计划的参与者将获得基于代金券的激励措施,以加强随访的出勤率,在随访中,他们将获得支持,以管理副作用和解决问题的依从性问题,补充他们所选择的方法,并在指示时协助转换方法。将向分配到常规护理条件的参与者提供有关避孕选择的一般信息以及提供避孕服务的诊所和提供者的联系信息。将在试验开始后1、3和6个月计划的评估中评价所有受试者的避孕措施使用情况。拟议的项目将是一项开创性的干预研究,以提高OM妇女更有效地使用避孕药具,并朝着制定一个有效的,以经验为基础的避孕管理计划,可以传播到全国各地的药物治疗设施的总体目标迈出了第一步。拟议的研究还具有影响公共卫生的巨大潜力,因为有效计划的制定将有助于减少药物依赖和非药物依赖妇女意外怀孕相关的巨大经济和社会成本。 公共卫生关系:每10名怀孕的阿片类药物依赖妇女中有近9人报告说,目前的怀孕是无意的,大多数非怀孕的阿片类药物维持妇女不使用避孕措施或使用避孕套等效果较差的方法。该申请的主要目的是开发和测试一种新的避孕管理计划,以增加阿片类药物维持妇女中更有效避孕药的使用。拟议的研究可能会减少阿片类药物依赖妇女的意外怀孕,所获得的知识也将对解决普通人群中意外怀孕率高的问题产生影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sarah H Heil其他文献

Sarah H Heil的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sarah H Heil', 18)}}的其他基金

Medically-supervised withdrawal vs. agonist maintenance in the treatment of pregnant women with opioid use disorder: Maternal, fetal, and neonatal outcomes
治疗患有阿片类药物使用障碍的孕妇的医学监督戒断与激动剂维持治疗:孕产妇、胎儿和新生儿结局
  • 批准号:
    9903275
  • 财政年份:
    2018
  • 资助金额:
    $ 30.2万
  • 项目类别:
Medically-supervised withdrawal vs. agonist maintenance in the treatment of pregnant women with opioid use disorder: Maternal, fetal, and neonatal outcomes
治疗患有阿片类药物使用障碍的孕妇的医学监督戒断与激动剂维持治疗:孕产妇、胎儿和新生儿结局
  • 批准号:
    10375543
  • 财政年份:
    2018
  • 资助金额:
    $ 30.2万
  • 项目类别:
Improving Effective Contraceptive use Among Opioid-Maintained Women: Stage II
改善使用阿片类药物的女性的有效避孕方法:第二阶段
  • 批准号:
    8759161
  • 财政年份:
    2014
  • 资助金额:
    $ 30.2万
  • 项目类别:
Low Nicotine Content Cigarettes in Vulnerable Populations: Pregnant Women
弱势人群中的低尼古丁含量香烟:孕妇
  • 批准号:
    10477410
  • 财政年份:
    2013
  • 资助金额:
    $ 30.2万
  • 项目类别:
Low Nicotine Content Cigarettes in Vulnerable Populations: Pregnant Women
弱势人群中的低尼古丁含量香烟:孕妇
  • 批准号:
    10247030
  • 财政年份:
    2013
  • 资助金额:
    $ 30.2万
  • 项目类别:
Testing the Reliability and Validity of Pupil Diameter in Opioid-exposed neonates
测试阿片类药物暴露新生儿瞳孔直径的可靠性和有效性
  • 批准号:
    8293516
  • 财政年份:
    2012
  • 资助金额:
    $ 30.2万
  • 项目类别:
Testing the Reliability and Validity of Pupil Diameter in Opioid-exposed neonates
测试阿片类药物暴露新生儿瞳孔直径的可靠性和有效性
  • 批准号:
    8699737
  • 财政年份:
    2012
  • 资助金额:
    $ 30.2万
  • 项目类别:
Testing the Reliability and Validity of Pupil Diameter in Opioid-exposed neonates
测试阿片类药物暴露新生儿瞳孔直径的可靠性和有效性
  • 批准号:
    8545754
  • 财政年份:
    2012
  • 资助金额:
    $ 30.2万
  • 项目类别:
Improving effective contraceptive use among opioid-maintained women
改善使用阿片类药物的女性的有效避孕方法
  • 批准号:
    8309018
  • 财政年份:
    2011
  • 资助金额:
    $ 30.2万
  • 项目类别:
CLINICAL TRIAL: MOTHER
临床试验:母亲
  • 批准号:
    7952101
  • 财政年份:
    2009
  • 资助金额:
    $ 30.2万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 30.2万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 30.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 30.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 30.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 30.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 30.2万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 30.2万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 30.2万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 30.2万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 30.2万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了